TWi Pharmaceuticals officially launches the merchandised Sorafenib Tosylate Tablet in the US marketDec 26, 2022

TWi Pharmaceuticals, Inc. (“TWi”) today announced the official launch of Sorafenib Tosylate Tablet (Equivalent to Nexavar®), which was merchandised from Yabao Pharmaceutical Co., Ltd.Beijing(“Yabao”), via its fully owned US subsidiary, TWi Pharmaceuticals USA, Inc. Product is available for immediate shipment.
Sorafenib Tosylate Tablet is used to treat patients with advanced hepatocellular carcinoma (HCC) that has spread to other parts of the body or cannot be treated with surgery and is not suitable for local treatment or with failure of local treatment ;; patients with a certain type of thyroid cancer that has spread to other parts of the body and cannot be treated with radioactive iodine. The brand drug is Nexavar®, which is owned by Bayer. According to the database of the US FDA, there are currently 4 approved generic drug certificates of Sorafenib Tosylate Tablet in the US. In addition to Yabao, the holders of the other 3 generic drug certificates are Mylan, Teva and DR REDDYS. According to IQVIA data, the total sales of Sorafenib Tosylate Tablet in the US were approximately US$61 million for the 12 months ended October 2022.
TWi Pharma and Yabao reached a distribution agreement for Sorafenib Tosylate Tablet in June 2021 (before TWi joined into Bora Group). Yabao is the drug certificate owner of Sorafenib Tosylate Tablet, and then TWi was granted with the distribution right of the product in the US and Taiwan.
For more information please visit www.twipharma.com